Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Free Cash Flow (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Free Cash Flow readings, the most recent being -$2.6 million for Q4 2017.

  • On a quarterly basis, Free Cash Flow fell 104.14% to -$2.6 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$14.9 million, a 202.94% decrease, with the full-year FY2025 number at -$62.3 million, down 31.88% from a year prior.
  • Free Cash Flow hit -$2.6 million in Q4 2017 for Eledon Pharmaceuticals, up from -$3.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $7.6 million in Q2 2016 to a low of -$11.2 million in Q2 2015.
  • Median Free Cash Flow over the past 5 years was -$5.4 million (2014), compared with a mean of -$5.3 million.
  • Biggest five-year swings in Free Cash Flow: surged 168.01% in 2016 and later plummeted 205.88% in 2017.
  • Eledon Pharmaceuticals' Free Cash Flow stood at -$6.8 million in 2013, then grew by 5.35% to -$6.5 million in 2014, then crashed by 40.76% to -$9.1 million in 2015, then skyrocketed by 85.93% to -$1.3 million in 2016, then plummeted by 104.14% to -$2.6 million in 2017.
  • The last three reported values for Free Cash Flow were -$2.6 million (Q4 2017), -$3.4 million (Q3 2017), and -$8.0 million (Q2 2017) per Business Quant data.